Ostrowski M L, Unni K K, Banks P M, Shives T C, Evans R G, O'Connell M J, Taylor W F
Cancer. 1986 Dec 15;58(12):2646-55. doi: 10.1002/1097-0142(19861215)58:12<2646::aid-cncr2820581217>3.0.co;2-u.
A total of 422 patients with malignant lymphoma of bone who were seen at the Mayo Clinic from 1907 through 1982 were placed into four major groups based on stage of disease. There was one group with primary lymphoma of bone, one group with multifocal osseous lymphoma, and two groups with lymphoma of bone and nodal or soft tissue (or both) disease. The last-mentioned two groups were separated on the basis of time of onset of osseous lymphoma in relation to the nonosseous disease. The stage of disease was the single most important prognostic indicator of overall survival in malignant lymphoma of bone. The 5- and 10-year survival rates were, respectively, 58% and 53% for patients with primary bone lymphoma, 22% and 12.5% for patients with bone and nodal or soft tissue (or both) disease, and 42% and 35% for patients with multifocal osseous disease. Features having no significant prognostic value were sex of the patient, histologic grade of the lymphoma (according to the Working Formulation and the Kiel system), and presence of T-cell features or cleaved cells (or both). This study is not able to adequately address efficacy of treatment. In fact, treatment may be very important in outcome.
1907年至1982年间在梅奥诊所就诊的422例骨恶性淋巴瘤患者根据疾病分期分为四大组。一组为原发性骨淋巴瘤，一组为多灶性骨淋巴瘤，两组为骨淋巴瘤合并淋巴结或软组织（或两者皆有）疾病。最后提到的两组根据骨淋巴瘤相对于非骨疾病的发病时间进行区分。疾病分期是骨恶性淋巴瘤总体生存的唯一最重要的预后指标。原发性骨淋巴瘤患者的5年和10年生存率分别为58%和53%，骨淋巴瘤合并淋巴结或软组织（或两者皆有）疾病的患者为22%和12.5%，多灶性骨疾病患者为42%和35%。对预后无显著价值的特征包括患者性别、淋巴瘤的组织学分级（根据工作分类法和基尔系统）以及T细胞特征或核分裂细胞（或两者皆有）的存在。本研究无法充分探讨治疗效果。事实上，治疗可能对预后非常重要。
